{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:37Z","timestamp":1792166317608,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.annonc.2023.02.012","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:25:03Z","timestamp":1677583503000},"page":"468-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial"],"prefix":"10.1016","volume":"34","author":[{"given":"J.","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ponce","family":"Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Al-Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bernabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Robinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garcia Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Madroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Was\u0105g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Pretzenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2023.02.012_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/JCO.2015.62.0096","article-title":"Cancer genomics: diversity and disparity across ethnicity and geography","volume":"34","author":"Tan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2023.02.012_bib2","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2023.02.012_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.02.012_bib4","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2023.02.012_bib5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.annonc.2023.02.012_bib6","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2023.02.012_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2023.02.012_bib8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2023.02.012_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2023.02.012_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2023.02.012_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jtho.2015.09.006","article-title":"Patients with advanced non-small cell lung cancer: are research biopsies a barrier to participation in clinical trials?","volume":"11","author":"Lim","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2023.02.012_bib12","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ijrobp.2014.08.032","article-title":"Variation in mechanisms of acquired resistance among EGFR-mutant NSCLC patients with more than 1 postresistant biopsy: metastatic non-small cell lung cancer","volume":"90","author":"Piotrowska","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.annonc.2023.02.012_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI","volume":"10","author":"Hata","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7782","key":"10.1016\/j.annonc.2023.02.012_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A\u00a0view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2023.02.012_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mdx017","article-title":"Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA","volume":"28","author":"Remon","year":"2017","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2023.02.012_bib16","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2023.02.012_bib17","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/cncr.28964","article-title":"Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib","volume":"120","author":"Sorensen","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2023.02.012_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.32503","article-title":"Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer","volume":"126","author":"Papadimitrakopoulou","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2023.02.012_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non\u2013small cell lung cancer","volume":"12","author":"Jenkins","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.02.012_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1759-7714.12986","article-title":"Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer","volume":"10","author":"Pan","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2023.02.012_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2023.02.012_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001011","article-title":"Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients","volume":"5","author":"Pluzanski","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.annonc.2023.02.012_bib23","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.02.012_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2023.02.012_bib25","doi-asserted-by":"crossref","unstructured":"Hendriks LE, Kerr K, Menis J, et\u00a0al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","DOI":"10.1016\/j.annonc.2022.12.009"},{"issue":"4","key":"10.1016\/j.annonc.2023.02.012_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"issue":"22","key":"10.1016\/j.annonc.2023.02.012_bib27","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:16:09Z","timestamp":1760336169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0923753423000893"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.02.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}